CALL/VERTEX PHARMACEUTICALS/600/0.1/19.09.25 | Real-time BOERSE MUENCHEN 14:26:54 2024-06-26 EDT | ||
| 2.59 EUR | -1.52% |
|
| Current month | +29.50% | ||
| 1 month | +17.19% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-26 | 2.59 | -1.52% |
| 24-06-25 | 2.63 | -0.38% |
| 24-06-24 | 2.64 | +5.18% |
| 24-06-21 | 2.51 | +0.40% |
| 24-06-20 | 2.5 | +1.63% |
Real-time BOERSE MUENCHEN
Last update June 26, 2024 at 02:26 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Goldman Sachs |
| WKN | GG2SFA |
| ISIN | DE000GG2SFA2 |
| Date issued | 2024-01-18 |
| Strike | 600 $ |
| Maturity | 2025-09-19 (450 Days) |
| Parity | 10 : 1 |
| Emission price | 2.04 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.17 € |
|---|---|
| Lowest since issue | 0.98 € |
| Spread | 0.3 € |
| Spread % | 10.71% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
474
USD
Average target price
465.5
USD
Spread / Average Target
-1.79%
- Stock Market
- Warrants
- Warrant
